A. Temperature: Previously 37.8°C (100°F), now 37.2°C (99°F) — back toward normal range, indicating reduced inflammation or illness.

B. Mood: The client still reports irritability, so there's no significant improvement in mood.

C. Weight: The client gained 3 kg (6.6 lb). In a previously underweight or unwell client, weight gain can indicate better nutritional status or recovery.

D. Heart rate: Decreased from 120/min (tachycardia) to 95/min — still slightly elevated but much closer to normal, suggesting recovery or reduced stress/metabolic demand.

E. Sleep pattern: The client now gets 7–8 hours of sleep and no longer reports fatigue, indicating restoration of rest and energy levels.

F. Respiratory rate 16/min: This is within normal range, but it was already normal previously (18/min) — so no change, not a sign of improvement.

Hypokalemia: The client is receiving high-dose furosemide, a loop diuretic, which promotes significant excretion of potassium in urine. This puts the client at high risk for hypokalemia, which can cause muscle weakness, arrhythmias, and fatigue—especially dangerous in someone with heart failure.
Hypotension: Furosemide also causes fluid volume loss, which can lead to decreased blood pressure. This client already shows signs of fluid overload, and rapid diuresis could result in hypotension, especially in an older adult or one with compromised cardiovascular status.
Rationale for Incorrect Options:
• Hypoglycemia: Furosemide does not typically cause low blood glucose.
• Hypercalcemia: Loop diuretics like furosemide actually cause calcium loss, so hypocalcemia, not hypercalcemia, is a more likely risk.
• Hypernatremia: While possible with dehydration, hyponatremia is actually more common with diuretics due to water loss exceeding sodium loss.

A. "Folic acid is important for stimulating the immune system": Folic acid does not stimulate the immune system. It primarily supports cell growth and red blood cell formation, rather than immune function.

B. "Folic acid is given to increase the absorption of other medications": Folic acid does not affect the absorption of other medications. Its primary function is to prevent folate deficiency and support blood cell production.

C. "Folic acid is administered to minimize the manifestations of benign prostatic hyperplasia": Folic acid does not treat BPH. Its primary role is in the formation of blood cells and prevention of neural tube defects.

D. "Folic acid is important for the building of blood cells": Folic acid is essential for DNA synthesis and the production of red blood cells. A deficiency can lead to anemia and impaired blood cell production.

A. "I will discard the open injector pen after two months": The open injector pen should be discarded after 30 days, not two months, to ensure the medication's stability and effectiveness. Keeping it longer may reduce its potency.

B. "I will inject the medication into the muscle of my thigh": Exenatide should be injected subcutaneously, not into the muscle. Injecting into the muscle could lead to erratic absorption and reduced medication effectiveness.

C. "I will store open injector pens at room temperature": Exenatide should be stored in the refrigerator, not at room temperature. Storing it improperly can lead to a loss of medication potency and affect its therapeutic effect.

D. "I will take this medication one hour before morning and evening meals": Immediate-release exenatide should be taken 60 minutes before meals to maximize its effectiveness in controlling post-meal blood sugar levels.

A. "Asthma": Asthma is not a contraindication for sumatriptan. While it is important to monitor for any respiratory issues, sumatriptan is not specifically contraindicated for clients with asthma. However, care should still be taken in individuals with respiratory concerns.

B. "Kidney disease": Kidney disease is not an absolute contraindication for sumatriptan, but caution is needed in severe renal impairment. Impaired kidney function can slow the elimination of the drug, potentially leading to increased levels in the bloodstream.

C. "Rheumatoid arthritis": Rheumatoid arthritis is not a contraindication for sumatriptan. There is no direct interaction between sumatriptan and rheumatoid arthritis, so this condition does not prevent the safe use of the medication.

D. "Coronary artery disease": Sumatriptan is contraindicated in clients with coronary artery disease. This medication can cause vasoconstriction, which may worsen heart conditions and increase the risk of myocardial infarction or ischemia.

A. "I should not drive while taking this medication": Benzonatate can cause drowsiness, dizziness, or sedation. These side effects may impair the client’s ability to drive safely, making it important to avoid driving while taking the medication.

B. "This medication will help me cough up the mucus in my chest": Benzonatate is a cough suppressant, not an expectorant. It works by numbing the throat and lungs to reduce the urge to cough, but it does not help clear mucus from the chest.

C. "I should decrease my dietary fiber intake while taking this medication": There is no need to decrease dietary fiber intake while taking benzonatate. Fiber intake should generally remain adequate to prevent constipation, which can sometimes occur as a side effect.

D. "I can chew this medication if I have difficulty swallowing": Benzonatate should never be chewed, as it can cause serious side effects, including choking or numbing of the mouth and throat. The medication should be swallowed whole.

A. "Decreased thyroxine levels": Mannitol does not affect thyroxine levels. It is an osmotic diuretic used to reduce fluid buildup, not to influence thyroid function or hormone levels.

B. "Correction of atrial flutter": Mannitol is not used to treat arrhythmias such as atrial flutter. It works to decrease intracranial pressure or reduce fluid retention but has no direct effect on heart rhythm abnormalities.

C. "Reduced intracranial pressure": Mannitol is used to reduce intracranial pressure by drawing fluid out of the brain. This effect helps treat conditions like cerebral edema or increased pressure from head injuries or other neurological issues.

D. "Increased hemoglobin levels": Mannitol does not directly affect hemoglobin levels. Its primary role is in reducing fluid volume and intracranial pressure, not in impacting red blood cell production or hemoglobin levels.

A. "Phenytoin": Phenytoin is an anticonvulsant used to prevent seizures, not for adrenal insufficiency. It does not treat the underlying hormonal imbalances or symptoms associated with adrenal insufficiency.

B. "Calcitonin": Calcitonin is a medication used to treat conditions like osteoporosis or hypercalcemia, not adrenal insufficiency. It does not address the deficiency of adrenal hormones.

C. "Buspirone": Buspirone is an anxiolytic medication used to treat anxiety. It has no role in the management of adrenal insufficiency, which requires hormonal replacement therapy.

D. "Fludrocortisone": Fludrocortisone is a synthetic corticosteroid used to treat adrenal insufficiency. It helps to replace aldosterone, which is often deficient in clients with adrenal insufficiency, supporting fluid and electrolyte balance.

A. "This medication can cause constipation": Methimazole is more likely to cause symptoms such as rash, fever, or agranulocytosis, rather than constipation. Constipation is not a common side effect of this medication.

B. "I will contact the provider if my throat becomes sore": Methimazole can cause agranulocytosis, a condition that reduces white blood cells and increases the risk of infection. A sore throat could indicate this side effect, and the client should contact the provider immediately.

C. "I will weigh myself once a week while on this medication": Regular weight monitoring may be helpful for managing hyperthyroidism, but it is not the primary concern with methimazole. The focus should be on monitoring for signs of infection or hematologic issues.

D. "This medication should be taken as needed when symptoms occur": Methimazole should be taken regularly as prescribed, not on an as-needed basis. Consistent use is necessary to manage hyperthyroidism and prevent complications.

A. "Instruct the client to limit caffeine": While caffeine can irritate the bladder, which may worsen symptoms of BPH, the priority action when starting doxazosin is addressing the potential for orthostatic hypotension.

B. "Instruct the client to report headache": Headache is a potential side effect of doxazosin, and it is important to monitor for this symptom. However, the priority action for this client is to manage the potential for dizziness or fainting due to the first-dose effect.

C. "Measure the client's intake and output": Measuring intake and output is important for monitoring kidney function and fluid balance, but it is not the first priority when starting doxazosin.

D. "Administer the medication at bedtime": Doxazosin can cause orthostatic hypotension, particularly after the first dose, leading to dizziness or fainting. Administering the medication at bedtime minimizes the risk of these side effects by reducing the chance of the client experiencing dizziness while standing.